This company has been acquired
MITO Stock Overview
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Stealth BioTherapeutics Corp Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.32 |
52 Week High | US$1.03 |
52 Week Low | US$0.16 |
Beta | 1.46 |
1 Month Change | 1.75% |
3 Month Change | 3.76% |
1 Year Change | -68.00% |
3 Year Change | -95.86% |
5 Year Change | n/a |
Change since IPO | -97.31% |
Recent News & Updates
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide
Jun 01Stealth BioTherapeutics skyrockets on data for elamipretide studies
May 06FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide
Jan 06Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31Stealth Bio launches $3.2M registered direct offering
Nov 20Shareholder Returns
MITO | US Biotechs | US Market | |
---|---|---|---|
7D | -0.1% | 0.2% | 1.3% |
1Y | -68.0% | 10.2% | 29.8% |
Return vs Industry: MITO underperformed the US Biotechs industry which returned -14.2% over the past year.
Return vs Market: MITO underperformed the US Market which returned -21.5% over the past year.
Price Volatility
MITO volatility | |
---|---|
MITO Average Weekly Movement | 1.5% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MITO has not had significant price volatility in the past 3 months.
Volatility Over Time: MITO's weekly volatility has decreased from 14% to 2% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 38 | Reenie McCarthy | https://www.stealthbt.com |
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich’s ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber’s hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company’s product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson’s, Alzheimer’s, Huntington’s, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550.
Stealth BioTherapeutics Corp Fundamentals Summary
MITO fundamental statistics | |
---|---|
Market cap | US$23.54m |
Earnings (TTM) | -US$52.53m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs MITO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MITO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$52.53m |
Earnings | -US$52.53m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.71 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -30.1% |
How did MITO perform over the long term?
See historical performance and comparison